Abstract
We investigated the clinical response of chronic heart failure patients with beta(2)-adrenergic receptor Gln(27)-->Glu polymorphism treated for 6 months with carvedilol, a alpha/beta-antagonist with antioxidant properties. The 6-min. walk test, the left ventricular ejection fraction, heart rate, plasma norepinephrine and malondialdehyde, a stress oxidative marker, concentrations were evaluated at baseline and after treatment for 6 months with carvedilol in 33 stable chronic heart failure patients with the Gln(27)-->Glubeta(2)-adrenergic receptor polymorphism. Carvedilol significantly increased the left ventricular ejection fraction, while decreasing the heart rate and malondialdehyde plasma concentrations in chronic heart failure patients with the Glu(27)beta(2)-adrenergic receptor allele. There were however, no significant changes in patients with the Gln(27)beta(2)-adrenergic receptor variant.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adrenergic beta-2 Receptor Antagonists
-
Adrenergic beta-Antagonists / administration & dosage
-
Adrenergic beta-Antagonists / pharmacology
-
Adrenergic beta-Antagonists / therapeutic use*
-
Carbazoles / administration & dosage
-
Carbazoles / pharmacology
-
Carbazoles / therapeutic use*
-
Carvedilol
-
Chronic Disease
-
Down-Regulation
-
Female
-
Heart Failure / drug therapy*
-
Heart Failure / genetics
-
Heart Failure / metabolism
-
Heart Failure / physiopathology
-
Humans
-
Male
-
Malondialdehyde / blood
-
Middle Aged
-
Oxidative Stress / drug effects
-
Pharmacogenetics
-
Polymorphism, Genetic*
-
Propanolamines / administration & dosage
-
Propanolamines / pharmacology
-
Propanolamines / therapeutic use*
-
Receptors, Adrenergic, beta-2 / genetics*
-
Ventricular Function, Left / drug effects
-
Ventricular Function, Left / physiology
Substances
-
Adrenergic beta-2 Receptor Antagonists
-
Adrenergic beta-Antagonists
-
Carbazoles
-
Propanolamines
-
Receptors, Adrenergic, beta-2
-
Carvedilol
-
Malondialdehyde